MedTrace Logo

Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)

NCT00828477 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2009-06-10

No results posted yet for this study

Summary

The objective of this study is to evaluate and compare the comfort of bromfenac or nepafenac following SLT.

Conditions

  • Intraocular Pressure

Interventions

DRUG

Xibrom

Xibrom: two times a day for seven days in the first eye.

DRUG

Nevanac

Nevanac: three times a day for seven days in the second eye.

Sponsors & Collaborators

  • Bp Consulting, Inc

    lead NETWORK

Principal Investigators

  • Nate Kleinfeldt, M.D · Coburn-Kleinfeldt Eye Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00828477 on ClinicalTrials.gov